Insider trades by month
US insider trades, March 2026
The 14,721 open-market buys and sales by US company CEOs, executives and directors filed in March 2026.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Zenas BioPharmaZBIO | Open-market buy | 03/30–03/31 | 03/31 | 54,000 sh2 trades | $18.91avg. | $1,021,140 | +3.2% | |
Phibro Animal HealthPAHC | Open-market sale10b5-1 plan | 03/30–03/31 | 03/31 | 14,080 sh4 trades | $53.75avg. | $756,848.37 | −27.0% | |
Navios Maritime PartnersNMM | Open-market buy10b5-1 plan | 03/27–03/31 | 03/31 | 3,826 sh3 trades | $65.64avg. | $251,153.94 | +0.1% | |
Wheeler Real Estate Investment TrustWHLR | Open-market sale | 03/27–03/31 | 03/31 | 18,166 sh3 trades | $0.96avg. | $17,383.85 | −11.1% | |
Wheeler Real Estate Investment TrustWHLR | Open-market sale | 03/27–03/31 | 03/31 | 18,166 sh3 trades | $0.96avg. | $17,383.85 | −11.1% | |
Wheeler Real Estate Investment TrustWHLR | Open-market sale | 03/27–03/31 | 03/31 | 18,166 sh3 trades | $0.96avg. | $17,383.85 | −11.1% | |
SharplinkSBET | Open-market sale | 03/31 | 03/31 | 2,848 sh | $6.21 | $17,686.08 | −3.0% | |
Laura Lee StewartPresident and CEO | Sound Financial BancorpSFBC | Open-market sale10b5-1 plan | 03/31 | 03/31 | 900 sh | $44.13 | $39,717 | −8.3% |
DaxorDXR | Open-market buy | 03/31 | 03/31 | 1,000 sh | $9.90 | $9,900 | +5.0% | |
Ryan Michael LanceChairman and CEO | ConocophillipsCOP | Open-market sale | 03/31 | 03/31 | 113,221 sh | $132.71 | $15,025,558.91 | −24.4% |
Phibro Animal HealthPAHC | Open-market sale10b5-1 plan | 03/30–03/31 | 03/31 | 14,080 sh4 trades | $53.75avg. | $756,848.37 | −27.0% | |
Edgewise TherapeuticsEWTX | Open-market sale10b5-1 plan | 03/31 | 03/31 | 21,338 sh | $32.12 | $685,376.56 | −69.0% | |
Kimberly D. CamposCio & Cao | Universal Insurance HoldingsUVE | Open-market sale | 03/31 | 03/31 | 946 sh | $34.12 | $32,277.52 | −11.3% |
Globe LifeGL | Open-market sale | 03/31 | 03/31 | 8,800 sh3 trades | $136.61avg. | $1,202,161.2 | −33.1% | |
Hongbo LuDirector | Zenas BioPharmaZBIO | Open-market buy | 03/31 | 03/31 | 75,000 sh | $20.00 | $1,500,000 | +21.6% |
Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 03/27–03/31 | 03/31 | 57,180 sh4 trades | $13.14avg. | $751,302.98 | −11.1% | |
Charles D. StapletonDirector | Davey Tree Expert | Open-market sale | 03/31 | 03/31 | 4,496 sh | $27.60 | $124,089.6 | −32.1% |
Fairmount Funds ManagementDirector | Cogent BiosciencesCOGT | Open-market sale | 03/31 | 03/31 | 7,000,000 sh | $34.66 | $242,620,000 | −56.0% |
Velocity FinancialVEL | Open-market sale10b5-1 plan | 03/30–03/31 | 03/31 | 14,840 sh2 trades | $18.04avg. | $267,719.86 | −13.0% | |
CleneCLNN | Open-market sale | 03/27–03/31 | 03/31 | 100,997 sh3 trades | $4.89avg. | $494,012.18 | −19.0% |
Other months
- September 20261,445
- June 202620,298
- May 202614,504
- April 20269,432
- March 202614,721
- February 202610,638
- January 20267,844
- December 202512,093
- November 202511,751
- October 202513,072
- September 202513,090
- August 202514,381
- July 20258,748
- June 202511,426
- May 202511,415
- April 20256,792
- March 202512,399
- February 202510,686
- January 20258,151
- December 202416,069
- November 202416,983
- October 20248,518
- September 202410,511
- August 202414,013
- July 202410,847
- June 202412,704
- May 202412,649
- April 20248,608
- March 202417,622
- February 202413,916
- January 20249,748
- December 202314,239
- November 202312,685
- October 20236,365
- September 20239,845
- August 202312,892
- July 20237,232
- June 202311,204
- May 202313,009
- April 20235,870
- March 202313,084
- February 202311,300
- January 20238,626